⚠ Research Use Only / Laboratory Personnel Only: This article is for qualified laboratory personnel working with controlled in-vitro experiments or institutionally approved model-animal research. It is not a guide for personal, household, human, veterinary, diagnostic, cosmetic, or performance-enhancement use.
Any concentration or calculation shown below is a laboratory example only and must not be used as a human or veterinary dose.
IGF-1 LR3, also written as Long-[Arg3]-IGF-I, is an 83-amino-acid laboratory protein based on mature IGF-I. The “Long” designation refers to the added 13-amino-acid N-terminal extension sequence (MFPAMPLSSLFVN), not to a measured half-life; the plasma clearance of Long-[Arg3]-IGF-I in rats is faster than that of native IGF-I.[1][5]
Researchers use it in IGFBP-sensitive signaling studies and as a growth-factor supplement in defined mammalian cell-culture systems.[1][10]

Molecular identity
| Common name | IGF-1 LR3 / Long-[Arg3]-IGF-I |
| Length | 83 amino acids (70-residue mature IGF-I domain + 13-residue N-terminal extension) |
| Approximate molecular mass | About 9.1 kDa; the solution NMR structure (PDB 3LRI) reports a total mass of approximately 9.13 kDa[2] |
| CAS number listed by ChemIDplus | 143045-27-6 |
| Sequence | MFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA |
| Disulfide bonds | Three intramolecular disulfide bonds (six cysteine residues); correct pairing is required for native-like folding |
| Structural features | Three α-helices (backbone RMSD 0.82 ± 0.28 Å for helical regions); flexible C-terminal tail (8 residues); N-terminal extension with transient structural features described as a molten helix[2] |
The solution NMR structure of Long-[Arg3]-IGF-I (PDB 3LRI, Laajoki et al., J Biol Chem 2000) confirmed the 83-residue protein with three α-helices and a highly flexible C-terminal tail. Compared with wild-type IGF-I, the N-terminal IGF-I domain residues show substantial reorientation, interpreted as contributing to the reduced IGFBP binding affinity.[2]
A government-curated ChemIDplus record in PubChem lists 143045-27-6 for Long-[Arg3]-IGF-I.[3]
The folded protein contains three disulfide bonds. Intact mass can support molecular identity and overall oxidation state, but it cannot establish disulfide-bond connectivity, native folding, or biological potency by itself.
Misfolded disulfide isomers of IGF-I have been characterized that differ from the native pairing.[4]
What the two changes do
- N-terminal extension: The added sequence is
MFPAMPLSSLFVN. It changes the N-terminal region and helps reduce interaction with IGF-binding proteins. - Arg3 substitution: Glutamic acid at position 3 of mature IGF-I is replaced by arginine. This further lowers binding to several IGF-binding proteins.
The effect is not a fixed potency multiplier. In the original cell studies, Long-[Arg3]-IGF-I was more active than native IGF-I in cell lines that released IGF-binding proteins, but it was less active in a cell line with no detectable IGF-binding proteins (chick embryo fibroblasts).
This shows that the result depends on the model and test conditions.[1]
IGF-binding proteins and time in circulation
IGF-binding proteins can hold IGF-I in the surrounding fluid or blood and change how much free protein can reach a receptor. Long-[Arg3]-IGF-I binds much less strongly to these proteins.
In rat studies, it was removed from plasma faster than native IGF-I, not slower. For this reason, the article should not give a universal 20–30-hour plasma half-life for IGF-1 LR3.
Greater apparent potency in some models does not establish a longer plasma half-life; potency, receptor exposure, tissue distribution, and plasma clearance are distinct parameters.[5]
Faster plasma removal does not automatically mean weaker results in a laboratory model. Lower binding to IGF-binding proteins can leave more protein free to move into tissues or reach receptors.
The final result still depends on the animal model, study method, sampling time, concentration, and result being measured.[5]
How it activates the IGF-1 receptor
IGF-1R is a cell-surface receptor with tyrosine kinase activity. Cell studies show that three receptor tyrosines—Tyr1131, Tyr1135, and Tyr1136—are important for normal receptor activation.[6]
After IGF-1R is activated, it can recruit IRS proteins and activate PI3K-related signaling.[7] In specific cell systems it can also activate ERK-related pathways, with outcomes that depend on cell type and experimental conditions.
For example, Long R3 IGF-I was used in fetal sheep cardiomyocyte experiments to study the roles of ERK and PI3K in proliferation and binucleation endpoints.[8]
IGF-1 LR3 should not be described as causing “constant” receptor activation.
Signal strength and duration can change with the cell line, medium, concentration, receptor level, and sampling time. Notably, Voorhamme and Yandell (2006) found that LONG R3IGF-I activated both IGF-IR and insulin receptor (IR) in HEK293 cells, with a bell-shaped dose-response curve in which IGF-IR activation decreased at higher concentrations.[10]
A time-course experiment is needed when signaling duration is important.
Simple comparison with related IGF-I proteins
| Feature | Native IGF-I | Long-[Arg3]-IGF-I | DES(1-3) IGF-I |
|---|---|---|---|
| Length | 70 amino acids | 83 amino acids | 67 amino acids |
| Main structural difference | Reference mature sequence | 13-amino-acid extension plus Glu3→Arg | First three amino acids removed |
| IGF-binding-protein interaction | Normal high-affinity binding | Strongly reduced | Strongly reduced |
| Measured activity | Reference response | Depends on the amount of IGF-binding protein and the assay | Depends on the assay and test system |
| Common research reason | Study normal IGF-I and IGFBP regulation | Reduce the effect of IGF-binding proteins in a defined experiment | Study a shorter IGF-I analog with low IGFBP binding |
Rat tracer studies also found that DES(1-3) IGF-I remained mostly unbound and left plasma faster than native IGF-I. This supports the general point that lower IGFBP binding does not automatically create a longer plasma half-life.[9]
Common laboratory uses
- IGFBP-sensitive cell studies: It can help compare receptor signaling when IGF-binding proteins would otherwise reduce the free amount of native IGF-I.[1]
- Serum-free cell culture: LONG R3IGF-I supports the growth and survival of Chinese hamster ovary (CHO) cells in serum-free media at concentrations at least 200-fold lower than required for insulin. In HEK293 cells it acts as a more potent growth and survival factor than either insulin or native IGF-I, activating both IGF-IR and IR. The dose-response curve for IGF-IR activation is bell-shaped, decreasing at higher concentrations, so each cell system needs its own concentration-response test.[10]
- Receptor-pathway studies: It can be used to measure IGF-1R, PI3K, AKT, ERK, cell-growth, or differentiation endpoints under controlled conditions.[8]
Laboratory reconstitution, dilution, and storage
Laboratory configuration warning: The steps below are only for trained laboratory staff. They are not instructions for human or veterinary administration.
Do not use personal-use syringes, household equipment, or any solvent whose suitability for the specific batch has not been verified against the lot-specific COA or product documentation.
- Read the batch documents first. Check the vial content, active protein amount, added formulation ingredients, recommended solvent, storage conditions, purity test, mass result, endotoxin result, and microbial-count information before opening the vial.
- Use the solvent stated for the batch. Different products may specify water, 10 mM HCl, or 10 mM acetic acid as the reconstitution solvent; commercial COA specifications have ranged from 0.1–1.0 mg/mL up to a maximum of 1 mg/mL depending on the supplier. The lot-specific COA or product insert takes priority over any single published example.[11]
- Mix gently. Let the solvent contact the lyophilized material and mix with gentle swirling or slow pipetting. Do not shake hard. Check for visible particles before making further dilutions.
- Calculate from the real stock concentration. Use C1 × V1 = C2 × V2. If the COA gives an active-protein amount, use that value rather than the total powder weight.
- Cell-culture calculation example only. A 1 mg/mL stock equals 1,000,000 ng/mL. Preparing 10 mL at 10 ng/mL directly would require 0.1 µL of the original stock, which is too small for most common laboratory pipettes. A 1:100 intermediate gives 10 µg/mL (= 10 ng/µL). Adding 10 µL of that intermediate and bringing the final volume to 10 mL gives 10 ng/mL.
- Control low-concentration adsorption. Prepare intermediate and working dilutions in an assay-compatible matrix. When permitted by the experiment, use a validated carrier or stabilizer (e.g., 0.1% BSA) and low-protein-binding tubes to reduce adsorption losses to plastic surfaces. Carrier-free or serum-free assays require separate recovery and stability verification.
- Use batch-specific storage conditions. Protein stability depends on temperature, light, oxidation, salt level, container, and handling. ICH Q5C provides a general framework for biotechnological protein stability testing, but specific storage temperatures, retest periods, and freeze-thaw limits must come from the lot-specific COA and actual batch stability data. If the lot document states −20°C, keep the unopened vial dry and protected from light, and avoid repeated freeze-thaw cycles after reconstitution.[12]
Laboratory use only: The concentrations and calculations above are for controlled experimental preparation. They must not be used, converted, or described as human or veterinary dosing guidance.
How to read a research COA
A COA is a group of separate test results. One result cannot replace another.
The analytical categories described in ICH Q6B provide a useful framework for distinguishing identity, purity, quantity, potency, and relevant contaminants, although acceptance criteria for a research-use reagent remain product- and application-specific.[13]
- HPLC: The HPLC percentage shows chromatographic purity under the method listed on the COA. It does not prove the amino-acid sequence, correct folding, active protein content, sterility, endotoxin level, or biological activity. Some commercial IGF-1 LR3 products specify ≥98% by HPLC with SDS-PAGE as an orthogonal method; others specify ≥95% by SDS-PAGE alone. The required purity depends on the experimental application.
- Mass spectrometry: Intact-mass MS supports identity when the measured mass matches the expected form within the method’s tolerance. It does not replace a purity test and may not show whether every disulfide bond is paired correctly.
- Active protein content: Total powder weight, HPLC purity, water, salts, and actual protein content are different values. Use the batch’s active protein content for concentration calculations when it is provided.
- Water and residual solvents: These need their own validated tests and batch limits. A dry-looking lyophilized cake is not a water-content result.
- Endotoxin, microbial count, and sterility: These are separate tests. High HPLC purity or passing a solution through a 0.22 µm filter does not prove that the material is sterile or low in endotoxin. Commercial IGF-1 LR3 products commonly report endotoxin specifications such as <1 EU/µg.
- Biological activity: A cell-based activity result only applies to the stated cell system, endpoint, reference material, and calculation method. Commercial products may report ED50 values such as ≤2 ng/mL or <10 ng/mL in specific cell proliferation assays; these are batch-specific results, not universal potency standards.
There is no single HPLC purity number that makes a protein suitable for every experiment.
The laboratory must set acceptance limits that match the planned assay. A COA does not show that a material is safe, effective, or approved for human, veterinary, diagnostic, cosmetic, or other non-research use.
Research limits and compliance
Results from cultured cells or standardized model animals describe what happened under those exact test conditions. They do not prove the same result in another cell line, another animal model, or a person.
The article should therefore avoid claims about treatment, body composition, skin care, anti-aging, glucose control, recovery, or any other personal effect.
LongR3-IGF-I has also been studied as a substance that anti-doping laboratories can test for using immunopurification and high-resolution mass spectrometry.[14] The World Anti-Doping Agency’s 2026 Prohibited List took effect on January 1, 2026 and places IGF-I and its analogs in section S2.3 (Growth Factors and Growth Factor Modulators), a category prohibited at all times in WADA-governed sport.[15]
Authoritative research references
- Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology. 1992;8(3):213-223. PMID: 1378742. PubMed.
- Laajoki LG, Francis GL, Wallace JC, Carver JA, Keniry MA. Solution structure and backbone dynamics of Long-[Arg3]-insulin-like growth factor-I. Journal of Biological Chemistry. 2000;275(14):10009-10015. doi:10.1074/jbc.275.14.10009. PDB: 3LRI. RCSB PDB.
- National Library of Medicine ChemIDplus/PubChem. Long-(arg3)insulin-like growth factor-I; PubChem Substance SID 381123731. PubChem.
- Milner SJ, Carver JA, Ballard FJ, Francis GL. Probing the disulfide folding pathway of insulin-like growth factor-I. Biotechnology and Bioengineering. 1999;62(6):693-703. PMID: 9951525. PubMed.
- Ballard FJ, Walton PE, Bastian S, Tomas FM, Wallace JC, Francis GL. Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs. Growth Regulation. 1993;3(1):40-44. PMID: 7683526. PubMed.
- Kato H, Faria TN, Stannard B, Roberts CT Jr, LeRoith D. Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I receptor in IGF-I action. Molecular Endocrinology. 1994;8(1):40-50. doi:10.1210/mend.8.1.7512194. PubMed.
- Myers MG Jr, Sun XJ, Cheatham B, et al. IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to phosphatidylinositol 3-kinase. Endocrinology. 1993;132(4):1421-1430. doi:10.1210/endo.132.4.8384986. PubMed.
- Sundgren NC, Giraud GD, Schultz JM, Lasarev MR, Stork PJS, Thornburg KL. Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1-induced proliferation of fetal sheep cardiomyocytes. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2003;285(6):R1481-R1489. doi:10.1152/ajpregu.00232.2003. PubMed.
- Ballard FJ, Knowles SE, Walton PE, et al. Plasma clearance and tissue distribution of labelled IGF-I, IGF-II and des(1-3)IGF-I in rats. Journal of Endocrinology. 1991;128(2):197-204. doi:10.1677/joe.0.1280197. PubMed.
- Voorhamme D, Yandell CA. LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. Molecular Biotechnology. 2006;34(2):201-204. doi:10.1385/mb:34:2:201. PubMed.
- Takaoka M, Smith CE, Mashiba MK, Okawa T, Andl CD, El-Deiry WS, Nakagawa H. EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2006;290(2):G404-G416. doi:10.1152/ajpgi.00344.2005. PMID: 16210470. PMC.
- U.S. Food and Drug Administration. ICH Q5C: Quality of Biotechnological Products—Stability Testing of Biotechnological/Biological Products. FDA Q5C.
- U.S. Food and Drug Administration. ICH Q6B: Specifications—Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. FDA Q6B.
- Mongongu C, Coudoré F, Domergue V, Ericsson M, Buisson C, Marchand A. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high-resolution mass spectrometry for anti-doping purposes. Drug Testing and Analysis. 2021;13(7):1256-1269. doi:10.1002/dta.3017. PubMed.
- World Anti-Doping Agency. 2026 Prohibited List (effective 1 January 2026). Section S2.3: Growth Factors and Growth Factor Modulators. WADA.
Research Use Only Disclaimer
Research Use Only: All SaiyanMed products are intended and labeled solely for laboratory research use. They are not intended, manufactured, tested, or released for human or veterinary administration.
This article provides general scientific information regarding standard laboratory in vitro and in vivo research contexts only, and does not constitute a validated experimental protocol, medical guidance, clinical guidance, veterinary guidance, or treatment advice.